Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon to Test Compounds with Nuevolution's Chematics

NEW YORK (GenomeWeb News) – Lexicon Pharmaceuticals said today it will use Nuevolution’s technology to identify small molecule lead compounds against a range of highly validated drug targets.
Under the agreement, Lexicon will pay Nuevolution an upfront payment and would also pay milestone payments and royalties on compounds that are identified using the Nuevolution Chemetics technology if candidate molecules advance through preclinical and clinical development and onto the market.
Copenhagen, Denmark-based Nuevolution also will have a future option to expand its involvement through a cost and profit sharing arrangement.
Lexicon specifically will use Nuevolution’s Chemetics platform to screen multiple fragment-based small molecule libraries. The validated targets were identified using Lexicon’s Genome5000 program, which the company used to explore physiological and behavioral function for nearly 5,000 genes by studying corresponding genes in knockout mice.
Nuevolution uses DNA labeling as part of its Chematics fragment-based drug screening platform, which helps identifty potent drug leads of higher quality and more quickly than other high-throughout screening approaches, according to the company.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.